Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban
Neurocritical Care · 2026-08 · 45 (1) · 200-207
DOI: 10.1007/s12028-026-02463-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurocritical Care, online erschienen am 03.03.2026. Verfasst von Franziska Lieschke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Rivaroxaban, Factor Xa, Factor Xa Inhibitors, Brain Injuries, Traumatic. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion Pharmaceuticals, Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Abstract (Originalsprache)
Objective
With the introduction of andexanet alfa, a specific antidote is now available to address life-threatening bleeding associated with factor Xa inhibitors. In this study, we explore its use in an experimental model of traumatic brain injury (TBI), mimicking a closed head trauma under rivaroxaban-induced anticoagulation.
Methods
Male C57BL6 mice were fed with rivaroxaban (10 mg/kg body weight). Subsequently, TBI was induced by controlled cortical impact (CCI) and andexanet alfa or placebo were administered as intravenous bolus injections. Edema and hemorrhage volume was quantified by magnetic resonance imaging (MRI) 24 h and 7 days after CCI. Functional outcome was assessed at day 1, 3, and 7 thereafter.
Results
Andexanet alfa led to reduced hemorrhage volume 24 h and 7 days after CCI as compared with control group without reversal of anticoagulation (2.9 ± 1.4 µl vs. 5.2 ± 3.3 µl, p = 0.02; 3.4 µl ± 1.5 µl vs. 5.5 µl ± 2.4 µl, p = 0.04). Along with the smaller hematoma sizes in the MRI, edema volume was significantly lower in mice treated with andexanet alfa 24 h and 7 days after CCI (−6.3% of contralateral hemisphere, p = 0.0002; and −7.1% of contralateral hemisphere, p = 0.006). While functional outcomes did not differ at 24 h following TBI, andexanet alfa improved neurological deficits after 7 days.
Conclusions
Our experimental data suggests that the use of andexanet alfa improves functional outcomes by reduction of factor Xa inhibitor–associated hematoma expansion in the subacute phase following TBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany.
- Department of Neurology with Experimental Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Department of Neurology, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Germany. bohmann@med.uni-frankfurt.de.
ORCID-Profile: Ferdinand O Bohmann
Förderung
- Alexion Pharmaceuticals
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
Zitieren
APA
Lieschke, F., Gelhard, S., Rosenthal-Rueckeis, M., Grefkes, C., & Bohmann, F. O. (2026). Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban. Neurocritical Care, 45(1), 200-207. https://doi.org/10.1007/s12028-026-02463-w
Vancouver
Lieschke F, Gelhard S, Rosenthal-Rueckeis M, Grefkes C, Bohmann FO. Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban. Neurocritical Care. 2026;45(1):200-207. doi:10.1007/s12028-026-02463-w
BibTeX
@article{Lieschke2026,
author = {Lieschke, Franziska and Gelhard, Sarah and Rosenthal-Rueckeis, Michelle and Grefkes, Christian and Bohmann, Ferdinand O},
title = {Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban},
journal = {Neurocritical Care},
year = {2026},
volume = {45},
number = {1},
pages = {200--207},
doi = {10.1007/s12028-026-02463-w}
}
EUVIMED